Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: Pre-op Radiation with Abemaciclib and Letrozole
NCT06139107Phase 1Recruiting
- Sponsor
- Mridula George
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by Mridula George. Primary endpoint: Safety and tolerability of the combination of abemaciclib and radiation at 5 years. Started Aug 2024; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT06139107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139107.